First isolation of SARS-CoV-2 from clinical samples in India

Sarkale, Prasad; Patil, Savita; Yadav, Pragya D; Nyayanit, Dimpal A; Sapkal, Gajanan; Baradkar, Shrikant; Lakra, Rajen; Shete-Aich, Anita; Prasad, SR; Basu, Atanu; Dar, Lalit; Vipat, Veena; Giri, Sidhartha; Potdar, Varsha; Choudhary, Manohar Lal; Praharaj, Ira; Jain, Amita; Malhotra, Bharati; Gawande, Pranita; Kalele, Kaumudi; Gupta, Nivedita; Cherian, Sarah; Abraham, Priya

doi:10.4103/ijmr.ijmr_1029_20

Cited by 103 publications

(36 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virus strain (NIV-2020-770) containing the Asp614Gly mutation, isolated from a COVID-19 patient and sequenced at the Indian Council of Medical Research National Institute of Virology, was provided to Bharat Biotech. 10 Biosafety level 3 manufacturing facilities and a well established Vero cell manufacturing platform (with proven safety in other licensed live and inactivated vaccines) were used for the rapid development of BBV152. 11 , 12 , 13 , 14 , 15 , 16 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Ella

Vadrevu

Jogdand

et al. 2021

The Lancet Infectious Diseases

Self Cite

366

352

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

“…The NIV-2020-770 strain contains the Asp614Gly mutation, which is characterised by aspartic acid to glycine shift at the amino acid position 614 of the spike protein. 10 …”

Section: Methodsmentioning

confidence: 99%

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Ella

Vadrevu

Jogdand

et al. 2021

The Lancet Infectious Diseases

Self Cite

366

352

View full text Add to dashboard Cite

“…After completion of twenty eight-days of immunization, animals were shifted to animal biosafety level-4 facility. Animals were challenged with 1 ml of SARS-CoV-2 (P-3, NIV-2020770, TCID50 10 6.5 /ml) 19 intratracheally and 0.25 ml in each nostril. Animals were monitored twice daily and clinical scoring was performed based on parameters as listed in Supplementary Table 3.…”

Section: Study Design and Experiments On Rhesus Macaquesmentioning

confidence: 99%

“…Media with 2% FBS was added to each well and was incubated in a CO 2 incubator at 37°C for 5 days. The culture plate was examined daily for CPE using an inverted microscope (Nikon, Eclipse Ti, Japan) 19 . The cell culture supernatant from the wells showing CPE was further con rmed by real-time RT-PCR 21 .…”

Section: Lymphocyte Subset and Cytokine/chemokine Pro Lementioning

confidence: 99%

Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques

Yadav¹,

Ella²,

Kumar³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic is a global health crisis that has severely affected mankind and posed a great challenge to the public health system of affected countries. The availability of a safe and effective vaccine is the need of the hour to overcome this crisis. Here, we have developed and assessed the protective efficacy and immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in rhesus macaques (Macaca mulata). Twenty macaques were divided into four groups of five animals each. One group was administered a placebo while three groups were immunized with three different vaccine candidates at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 fourteen days after the second dose. The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralizing antibody titers from 3rd-week post-immunization. Viral clearance was observed from bronchoalveolar lavage fluid, nasal swab, throat swab, and lung tissues at 7 days post-infection in the vaccinated groups. No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which showed features of interstitial pneumonia and localization of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry. Data from this study substantiate the immunogenicity of the vaccine candidates and BBV152 is being evaluated in Phase I clinical trials in India (NCT04471519).

show abstract

“…Apart from its intrinsically lower risk factor with regard to human health, the suitability of Alphacoronavirus 1 for infectivity experiments consists in its replication to high titres. In contrast, SARS-CoV-2 cultivated in VERO cells achieves only low titres, placing limitations on such experiments (Keil et al 2020;Sarkale et al 2020).…”

Section: Introductionmentioning

confidence: 99%

Coronavirus Persistence on a Plastic Carrier Under Refrigeration Conditions and Its Reduction Using Wet Wiping Technique, with Respect to Food Safety

Malenovská

2020

Food Environ Virol

View full text Add to dashboard Cite

The global SARS-CoV-2 pandemic dictates that anti-contagion strategies should become matters of essential routine in everyday life. Fomite transference is one of the routes of transmission that has been considered for this virus. However, the risks associated with contaminated surfaces of food packaging kept in refrigerators have not yet been adequately assessed. In this study, a surrogate virus, Alphacoronavirus 1, was used to investigate the persistence of coronavirus dried on a plastic carrier at 4 °C. Techniques of wet wiping, with or without disinfectant saturation, were employed to evaluate their effectiveness in the elimination of the virus. If not wiped, the loss of infectivity of the virus on plastic surfaces was, on average, 0.93 log 10 (i.e. 83%) per day of storage at 4 °C. Wiping with water-saturated material reduced the initial virus titre on the plastic carrier by 2.4 log 10 (99.6%); the same results were achieved through wiping with bactericidal wipes containing ethanol. Wipes saturated with a combination of disinfectant agents (didecyl-dimethyl-ammonium chloride, hydrogen peroxide) decreased the virus titre still more efficiently, by 3.8 log 10 (99.98%) and also significantly prevented further transfer of the virus to a secondary surface through wiping. Thus SARS-CoV-2 transmission potential via contaminated plastic packaging and food may be efficiently eliminated by wet-wiping, especially when wipes saturated with specific disinfectants are used.

show abstract

First isolation of SARS-CoV-2 from clinical samples in India

Cited by 103 publications

References 18 publications

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques

Coronavirus Persistence on a Plastic Carrier Under Refrigeration Conditions and Its Reduction Using Wet Wiping Technique, with Respect to Food Safety

Contact Info

Product

Resources

About